PharmaGap Inc.
OTC Bulletin Board : PHRGF

PharmaGap Inc.

September 29, 2011 08:43 ET

PharmaGap Adds to Patent Portfolio For GAP-107B8 Cancer Drug; Expands Claims

OTTAWA, ONTARIO--(Marketwire - Sept. 29, 2011) - PharmaGap Inc. (TSX VENTURE:GAP) (OTCBB:PHRGF) ("PharmaGap" or "the Company") is pleased to announce the first of two provisional patent applications with the United States Patent and Trademark Office ("USPTO") covering the results of development of PharmaGap's lead cancer drug GAP-107B8 during 2011 to date. These provisional patent filings covering the GAP-107B8 formulations represent significant steps forward in the Company's ability to realize value from the Company's drug development program.

This filing, titled "Anti-Cancer Peptides and Uses Thereof", addresses both the original and modified forms of GAP-107B8. The modified version of GAP-107B8 has been created through the application of commonly used drug formulation techniques in order to advantageously adjust the molecular properties of GAP-107B8 to enhance stability and biological activity of a drug compound while maintaining its essential nature.

This filing also expands previous claims for GAP-107B8, and specifically addresses methods of treating malignant ascites (a severe and common morbidity occurrence in ovarian cancer and other cancers listed below), of treating or preventing metastasis of a cancer, and for the inhibition of Akt expression. Akt is a serine/threonine protein kinase that plays a key role in multiple cellular processes (cell motility and invasion, hormone independence, and chemotherapy and radiation resistance) and has been implicated as a major factor in many types of cancer, including certain breast cancers, pancreatic cancers, colorectal cancers, gastric cancers and ovarian cancers.

About PharmaGap Inc.

PharmaGap Inc. (TSX VENTURE:GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug that has been shown to be highly cytotoxic to numerous cancer types, including chemo-resistant cancers, in vitro. For more information on PharmaGap please visit the Company's website at

Forward Looking Statements

This news release contains certain statements that constitute forward-looking statements as they relate to the Company and its management. Forward-looking statements are not historical facts but represent management's current expectations of future events, and can be identified by words such as "believe", "expects", "will", "intends", "plans", "projects", "anticipates", "estimates", "continues", and similar expressions. Although management believes that expectations represented in such forward-looking statements are reasonable, there can be no assurance that they will prove to be correct.

By their nature, forward-looking statements include assumptions and are subject to inherent risks and uncertainties that could cause actual future results, conditions, actions or events to differ materially from those in the forward-looking statements. If and when forward-looking statements are set out in this news release, PharmaGap will also set out the material risk factors or assumptions used to develop the forward-looking statements. Except as expressly required by applicable securities laws, the Company assumes no obligation to update or revise any forward-looking statements. The future outcomes that relate to forward-looking statements may be influenced by many factors, including, but not limited to: results of ongoing product testing and development; regulatory approvals required to complete development of products; ability to manufacture product at quality and scale for human use on an economically sound basis; patient reimbursement by private and public health insurance programs; unintended side effects of products; competitive products; product liability; intellectual property; reliance on key personnel; risks of future legal proceedings; income tax matters; availability and terms of financing; distribution of securities; effect of market interest rates on price of securities, and potential dilution.

Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.

Contact Information